Connect
← Return to Datopotamab Dxd; Dato-dxd, Datroway, ADC for a few metastatic cancers
Discussion
Datopotamab Dxd; Dato-dxd, Datroway, ADC for a few metastatic cancers
Lung Cancer | Last Active: 1 day ago | Replies (3)Comment receiving replies
Hi @olivia7850, I'm not an expert, but I believe Dato-dxd is fairly newly FDA approved for lung cancer also. It's approved for EGFR based lung cancers, so only a slice of the overall lung cancer population (10-15%). Hopefully continuing research will show effectiveness for additional types too.
If one of our lung cancer members have had experience with Datroway/Data-dxd I hope they respond too. 🙂
Wishing you the best of luck with your search for treatment. I have had an early-stage breast cancer (1B), but also have a metastatic lung cancer. So, I understand the continual search for effective treatments and the hope that treatment approvals stay ahead of our needs and recurrences.
Replies to "Hi @olivia7850, I'm not an expert, but I believe Dato-dxd is fairly newly FDA approved for..."
Connect
@lls8000
Hello Lisa:
The FDA has announced that the approval for Dato-Dxd use for in metastatic triple negative breast cancer or unresectable (cannot be surgically removed) triple negative breast cancer will be effective on May 2, 2026. That's great news and only a few weeks away.
Dato-Dxd is already approved for certain other breast cancers and for non small cell lung cancer (NSCLC).
This is fabulous news for mTNBC folks who have limited chemo/ADC options since we lack any hormone receptors. It's great to have another excellent ADC beyond sacituzumab govitecan.